• WCG’s eCOA portfolio and imaging analysis technology from NeuroRx are now part of Clario!

menu-close-icon
Your using an unsupported browser. Please update to a modern browser for a better experience.
Skip to content
Clario Clario
  • Solutions
    • Study Endpoints
        • Cardiac safety and efficacy endpoint solutions for all phases, anywhere in the world.

        • Collect continuous ECG data in site-based or hybrid trials with our flexible solutions and patient-friendly devices.

        • Collect and centrally analyze accurate, consistent, quality blood pressure data from site-based to hybrid trials.

        • Monitor every heartbeat with precision to assess safety and efficacy throughout your site-based or hybrid clinical trial.

        • Fulfill your ICH E14 requirement early, minimize risk and potentially reduce costs throughout your trial.

        • Leverage our key opinion leaders to understand the complex regulatory landscape while minimizing risk with confidence.

        • Make your clinical trials easier, faster, more engaging and accessible to all.

        • Enjoy flexible, fast and confidential site assessments at home.

        • Enhance your ePRO data with photo and audio capture.

        • Accelerate your clinical trial setup with Clario’s pre-validated and configured eCOA assessments.

        • Improve data accuracy and reduce variability in scoring with Clario’s training solutions.

        • Your trusted partner for the richest eCOA endpoint data in your clinical trial.

        • Monitor Suicide Ideation and Behavior (SIB) in clinical trials effectively with Clario’s suicide assessment tool, eC-SSRS.

        • Accelerate drug development and reduce risk with Clario’s comprehensive medical imaging core lab services.

        • The Clario team includes medical imaging experts and globally recognized key opinion leaders (KOLs) representing multiple disciplines.

        • Clario’s Image Redact AI automatically redacts sensitive patient identifiers from videos, photos and PDFs.

        • Secure accurate results, streamline your processes, and meet your unique needs with our imaging platform.

        • Leverage our full range of medical imaging and diagnostic imaging modalities, including CT Scans, Endoscopy, MRIs, and more.

        • Securely collect, store, and share de-identified images for compliance with 21 CFR Part 11 and EU GDPR standards.

        • Clario's complete solution for measuring objective digital endpoints of mobility with wearable sensor technology.

        • The Opal V2R® is a research grade wearable sensor that delivers meaningful outcomes and richer insights.

        • Explore more than 750 scientific publications that reflect the technical and clinical applications of Clario’s Opal® System.

        • Everything you need for high quality, low variability pulmonary function data and high patient compliance for clinical trials.

        • Centralized, on-site pulmonary function testing for clinical trials.

        • Remote spirometry testing for respiratory clinical trials.

        • Assess cough frequency, cough severity and other lung sounds such as crackles or rhonchi for clinical trials.

        • Assess the capacity of the lungs for effective gas transfer.

        • Advanced, cloud-native technologies and clinical trial software to screen, clean, QC and assess complicated data.

        • Collect, centralize and manage participant screening and eligibility data with customized workflows.

        • Boost stakeholder insights with business intelligence (BI) tools, analytics for endpoint and safety risks, and data exchange solutions.

        • Securely collect, store and share compliant images in the cloud to keep clinical trial sponsors and labs informed.

    • Segments
    • Study Phases
    • Technology
  • Therapeutic Areas
    • Cardiovascular & Metabolic Icon RGBCardiovascular & Metabolic
    • Dermatology Icon RGBDermatology
    • Type 2 Diabetes and Obesity iconDiabetes and Obesity
    • Gastroenterology Icon RGBGastroenterology
    • Hepatology Icon RGBHepatology
    • Infectious Disease Icon RGBInfectious Diseases
    • Muskoskeletal Icon RGBMusculoskeletal
    • Neuroscience Icon RGBNeuroscience
      • Neuroscience Indications
    • Oncology Icon RGBOncology
    • Ophthalmology Icon RGBOphthalmology
    • Respiratory Solutions IconRespiratory
  • Resources
    • Blog Articles
    • Case Studies
    • Downloads
    • Events
    • External Publications
    • Webinars
  • About
    • The Clario Story
    • Careers
    • Corporate & Social Responsibility
    • Information Security
    • Leadership
    • Legal & Privacy
    • Newsroom
    • Scientific Expertise
    • Strategic Partnerships
    • Values & Culture
  • Support
    • Customer Support
    • In-Country Cardiac Safety Support
  • Solutions
    • Study Endpoints
      • Cardiac Solutions
        • Cardiac Solutions
        • Arrhythmia Analysis
        • Blood Pressure Services
        • ECG — On-site to DCT and Phase I-IV
        • Phase I/TQT Cardiac Assessment
        • Regulatory Consultation and Statistical Analysis Expertise
      • Clinical Adjudication
      • eCOA
        • eCOA Clinical Trials
        • eCOA Live
        • eCOA Multimedia
        • eCOA Rapid Start
        • eCOA Rater and Participant Training
        • eCOA Rescue Studies
        • Suicidal Ideation
      • Medical Imaging
        • Medical Imaging
        • Image Redact AI
        • Imaging Platform
        • Medical Imaging Science Team
        • Modalities
        • SMART Submit
      • Precision Motion
        • Precision Motion for Clinical Trials
        • Precision Motion for Research
        • Precision Motion: Scientific Publications
      • Respiratory Solutions
        • Respiratory Solutions
        • Site-Based Spirometry
        • Virtual Home Spirometry
        • Cough and Lung Sounds
        • Diffusing Capacity (DLCO)
      • Trial Enablement
        • Trial Enablement
        • Eligibility Solution
        • Reporting & Analytics
        • Source Document Manager
    • Segments
      • Biotechs
      • CROs
      • Pharma
    • Study Phases
      • Phase I
      • Phase II/III
    • Technology
      • Artificial Intelligence (AI)
      • Hybrid Trials
  • Therapeutic Areas
    • Cardiovascular & Metabolic
    • Dermatology
    • Diabetes and Obesity
    • Gastroenterology
    • Hepatology
    • Infectious Diseases
    • Musculoskeletal
    • Neuroscience
      • Dementias
      • Headache Disorders
      • Movement Disorders
      • Multiple Sclerosis
      • Pain Disorders
      • Psychiatric Disorders
    • Oncology
    • Ophthalmology
    • Respiratory
  • Resources
    • Blog Articles
    • Case Studies
    • Downloads
    • Events
    • External Publications
    • Webinars
  • About
    • The Clario Story
    • Corporate & Social Responsibility
    • Information Security
    • Leadership
    • Legal & Privacy
    • Scientific Expertise
    • Strategic Partnerships
    • Values & Culture
  • Support
    • Customer Support
    • In-Country Cardiac Safety Support
  • Careers
    • Life at Clario
  • Newsroom
  • Login
  • Contact sales
    • Log in
    • Contact sales
  1. Home Resources Blog Articles Researcher spotlight: Cameron Kirk, Ph.D.

Researcher spotlight: Cameron Kirk, Ph.D.

Precision Motion

cameron kirk headshot
cameron kirk headshot

Cameron Kirk, Ph.D.

Postdoctoral Research Scientist, Newcastle University

Opal® V2R Technology has been used by thousands of researchers worldwide and together, these researchers have published more than 800 peer reviewed papers, greatly contributing to available body of evidence in human movement.

APDM, now owned by Clario, has delivered deep scientific expertise and broad endpoint technologies to help transform lives around the world for more than 50 years. Our endpoint data solutions have been deployed over 26,000 times to support clinical trials in more than 100 countries. Our global team of science, technology, and operational experts have supported over 60% of all FDA drug approvals since 2012.

For more information, visit our Wearable Biosensors for Research page. 

Q:

Would you please introduce yourself, your academic background and your research interests?

A:

Having recently graduated with my Ph.D., I’m now a post-doctoral researcher continuing my work as part of the Brain and Movement Research Group within the Translational and Clinical Research Institute at Newcastle University. I have been a member of the Mobilise-D project from September 2019 until its completion in June 2024, specifically involved in the technical validation study where I contributed to the validation of algorithms to identify the most accurate and reliable analytical pipeline for estimating digital mobility outcomes, such as real-world walking speed, from a single lower-back-worn wearable device.

Digital mobility outcomes have the potential to measure changes in aspects of health that are most important to patients, such as their ability to walk safely and independently in their daily lives. These outcomes provide insight into our walking behaviors at a broad level (number of steps, number of walking bouts, average duration of walking) and functional gait performance (walking speed, stride length, and cadence). My research has focused on understanding how specifically DMOs can add value to the existing clinical assessment of Parkinson’s disease, as a powerful complementary tool. My research now extends to characterizing digital mobility outcomes in people living with Multiple System Atrophy, Sarcopenia, and Posterior Cortical Atrophy, a rare form of Alzheimer’s. I’m also fascinated by how environmental contextual data measured from GPS devices can be applied to improve our understanding of how the places we live, work, and socialize influence our quality of life and health outcomes.

Q:

Do you have a personal story that led to your interest in human movement/ neurodegenerative disease research? What continues to drive your ambitions as a scientist?

A:

During my time studying Sport and Clinical Biomechanics MSc at the Sport and Exercise Science Institute at Liverpool John Moore’s University, I had the privilege of attending meetings at the North-West Movement Analysis Centre at Alder Hey Children’s Hospital. Here, clinicians and researchers discussed optimal treatment approaches for improving mobility in children with various forms of cerebral palsy, guided by biomechanical analysis of gait kinematics obtained from three-dimensional motion capture. This was an eye-opening experience of the positive real-world impact that human movement science can have in improving people’s lives and ignited my career. My ambitions are driven by my own background, involved from sports from a young age, I know how important it is for people to remain healthy and active especially as we get older.

My ambitions are driven by my lifelong involvement in sports, which has given me strong appreciation for the importance of maintaining health and physical activity, particularly as we age. I’m passionate about the role that physical activity plays in promoting healthy, active aging, and I believe that everyone deserves the opportunity to enjoy a high quality of life well into their later years. My research is focused on identifying how mobility evolves over time and applying this information to develop strategies to preserve and enhance it, with the ultimate goal of helping people stay active, independent, and engaged in life as they grow older.

Q:

What research projects or questions are you currently working on?

A:

Following the conclusion of the Mobilise-D project, I’m currently working on several projects that implement digital mobility outcomes in their research. I’m part of a collaborative study with University College London (UCL) that aims to understand how real-world mobility is affected in people with Posterior Cortical Atrophy, a group that is significantly underserved in research. Much of my previous work has focused on Parkinson’s disease, so being involved in this study has been eye-opening. I’m also contributing to the Exenatide study, a therapeutic clinical intervention trial which has recruited participants with Parkinson’s and Multi-System Atrophy and has included digital mobility outcomes as secondary measures to assess changes in response to the therapeutic intervention. This is an exciting study to be part of, as it is one of the first clinical trials to incorporate digital mobility outcomes as key outcome measures.

Q:

Where do you see the use of wearable IMU’s in human movement research going in the next 5 years?

A:

Understanding how well people move in their daily lives has long been an important research topic. However, there were significant challenges in determining the most valid approach to measuring this, which were widely disputed. Recently, substantial progress has been made in addressing these questions in a unified manner, resulting in clear guidelines on the optimal approaches to measuring real-world mobility. This has significantly improved confidence in the adoption of IMUs (Inertial Measurement Units) in clinical studies. From my first-hand experience in research, I’ve observed a rapid increase in the number of studies incorporating IMUs. I’m currently working with multiple studies across a growing number of sites, both nationally and internationally, and involving more diverse clinical groups, which demonstrates that this has become a hot topic.

Building on the work of the Mobilise-D consortium, we have done the ‘hard yards’ in identifying the optimal approach to technically and clinically validating digital mobility outcomes. We have now made our pipeline openly available through the ‘mobgap’ package (https://github.com/mobilise-d/mobgap), allowing researchers not only to implement it in their own work but also to optimize the existing pipeline. This progress is really encouraging, and I anticipate a significant increase in both the quantity and quality of literature in this field as a result. Additionally, I hope to see more research being conducted in typically underserved countries, which would help promote a more diverse body of literature from a cultural perspective, an area that is currently limited.

Q:

Fill in the blank: When I’m not working on a research project, you can find me…

A:

Reading any fantasy or science-fiction book I can get my hands on. I’ve recently read The Will of the Many by James Islington and can’t recommend it enough. Being physically active is very important to me, I played rugby from an early age and have recently started Cross-fit, quickly becoming obsessed with it! I enjoy watching any sport (primarily rugby and football) – I’m also a long-suffering Aston Villa football fan and am looking forward to this season having qualified for the Champions League!

Related press release:

https://www.ihi.europa.eu/news-events/newsroom/real-world-results-mobilise-d-algorithms-enter-market

Learn more about Opal wearable sensors or be featured in an upcoming researcher spotlight

Contact Clario Precision Motion
Back to articles
Share
Twitter Facebook LinkedIn

Latest articles

See all articles
Article

Researcher spotlight: Clayton Swanson

Precision Motion

Read
Article

Researcher spotlight: Dr. Lauren Tueth

Precision Motion

Read
Article

Researcher spotlight: Brice Cleland

Precision Motion

Read
Clario logo
    • Solutions
    • Therapeutic Areas
    • About
    • Resources
    • Careers
    • Newsroom
  • Get in touch

    • Contact
    • Support
    • Customer portal

Follow us

Twitter LinkedIn Glassdoor
×

Contact sales

If you are looking for a partner to help you generate the richest clinical evidence with the right clinical trial technology, please fill in the form below.


Not what you're looking for?

Please visit our Contact Page for customer support, office locations, or media contacts.

  • © 2025 Clario

    • Legal and Privacy Terms
    • Information Security
    • Cookie Policy
    • Impressum